CJC-1295 vs 5-Amino-1MQ
Compare the research profiles of CJC-1295 and 5-Amino-1MQ. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesCJC-1295
CJC-1295 (with or without DAC)
growth-hormone
Phase 2 Clinical Trials
not-approved
5-Amino-1MQ
5-Amino-1-Methylquinolinium
metabolic
Preclinical
not-approved
Detailed Comparison
| Aspect | CJC-1295 | 5-Amino-1MQ |
|---|---|---|
| Overview | A growth hormone releasing hormone (GHRH) analog that stimulates GH release. Available with DAC (Drug Affinity Complex) for extended half-life or without for shorter action.... | A small molecule peptide gaining traction for targeting visceral fat and activating NAD+ levels to boost metabolic rate. Works by inhibiting NNMT enzyme.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics GHRH to stimulate the pituitary gland to produce and release growth hormone. The DAC version binds to albumin for prolonged effect.... | Inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that when overexpressed leads to fat accumulation. Blocking NNMT increases NAD+ levels and... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.